Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

SYDNEY, AUSTRALIA–22 January 2021–Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep”or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731